Ketorolac tromethamine doesn't reduce risk of severe ROP development

Article

Administering ketorolac tromethamine ophthalmic solution to preterm infants does not reduce the risk of developing severe retinopathy of prematurity (ROP).

Administering ketorolac tromethamine ophthalmic solution to preterm infants does not reduce the risk of developing severe retinopathy of prematurity (ROP), claims a study in the Journal of Pediatric Ophthalmology and Strabismus.

Dr Carmen Giannantonio et al., Division of Neonatology, Department of Pediatrics, Catholic University Sacred Heart, Rome, Italy, included 47 premature newborn infants who weighed 1000 g or less at a gestational age (GA) of 29 weeks.

Each infant was administered ketorolac tromethamine ophthalmic solution in one eye and a placebo solution in the other eye.

Out of the patients assessed, 45 infants developed ROP. Of the patients with ROP, six presented with various stages of ROP between the two eyes- four experienced a better outcome in the eye that received ketorolac tromethamine.

When evaluated according to GA the differences between ROP staging were not significant and no significant side effects were reported.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.